10x Genomics, Inc. Foreign Income Tax Expense (Benefit), Continuing Operations
10x Genomics, Inc. (TXG) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $2.15 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-13
- 10x Genomics, Inc. foreign income tax expense (benefit), continuing operations for fiscal 2024 was $2.15M, a 44.75% decline from fiscal 2023.
- 10x Genomics, Inc. foreign income tax expense (benefit), continuing operations for fiscal 2023 was $3.89M, a 155.45% increase from fiscal 2022.
- 10x Genomics, Inc. foreign income tax expense (benefit), continuing operations for fiscal 2022 was $1.52M, a 971.83% increase from fiscal 2021.
- 10x Genomics, Inc. foreign income tax expense (benefit), continuing operations for fiscal 2021 was $142.00K, a 99.66% decline from fiscal 2020.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2024-12-31 | $2.15M 10-K · filed 2026-02-13 |
| 2023-12-31 | $3.89M 10-K · filed 2026-02-13 |
| 2022-12-31 | $1.52M 10-K · filed 2025-02-13 |
| 2021-12-31 | $142.00K 10-K · filed 2024-02-15 |
| 2020-12-31 | $41.25M 10-K · filed 2023-02-16 |
| 2019-12-31 | $101.00K 10-K · filed 2022-02-18 |
| 2018-12-31 | $41.00K 10-K · filed 2020-02-27 |